None
Quote | HOOKIPA Pharma Inc. (NYSE:HOOK)
Last: | $ |
---|---|
Change Percent: | -3.60% |
Open: | $12.50 |
Close: | $12.04 |
High: | $12.6839 |
Low: | $12.00 |
Volume: | 80,315 |
Last Trade Date Time: | 02/12/2020 04:41:40 pm |
News | HOOKIPA Pharma Inc. (NYSE:HOOK)
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV) HOOKIPA achieves a $5 million non-dilutive milestone payment under its collabora...
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company’s selected registrati...
Message Board Posts | HOOKIPA Pharma Inc. (NYSE:HOOK)
Subject | By | Source | When |
---|---|---|---|
$HOOK Price gaining | trendzone | investorshub | 05/08/2023 2:04:57 AM |
https://stockcharts.com/h-sc/ui?s=hook&p=D&yr=0&mn=6&dy=0&id=p38090673899 | surf1944 | investorshub | 05/06/2023 1:43:55 PM |
Price gaining last up | MADDSTACKER | investorshub | 05/06/2023 2:03:59 AM |
znewcar1: $HOOK f54.7M Hod 1.78 w/ 21% v2,509,109 @1.6500 f54,722,339 | znewcar1 | investorshangout | 05/05/2023 7:49:29 PM |
what does this mean? | trendzone | investorshub | 05/04/2023 12:32:05 AM |
News, Short Squeeze, Breakout and More Instantly...
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV) HOOKIPA achieves a $5 million non-dilutive milestone payment under its collabora...
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company’s selected registrati...
Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20 Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc....